Background: The clinical applicability of the Revised EuropeanAmerican Lymphoma (R.E.A.L.) Classification has been demonstrated in several retrospective studies. The present, ongoing study was initiated to evaluate the clinical and pathological utility of the R.E.A.L. Classification compared with the Working Formulation (WF) in a prospective fashion, in an unselected patient population treated at a single institution.
Introduction
In 1994, the International Lymphoma Study Group (I.L.S.G.) proposed a new classification system for lymphomas -the Revised European-American Lymphoma (R.E.A.L.) Classification [1] . This system emphasizes immunophenotype and genotype, as well as classical morphology and clinical behaviour in the characterization of individual subtypes of non-Hodgkin's lyphoma (NHL). Since the publication of this proposal, several studies evaluating the clinical usefulness of this classification have been reported, including an analysis by the I.L.S.G. [2] [3] [4] [5] . All have been large scale, retrospective studies utilizing data from single or multi-centre clinical trials with initial patient diagnosis mostly preceding publication of the R.E.A.L. Classification. The aim of this on-going study is to evaluate the clinical and pathological utility of the R.E.A.L. Classification in a prospective fashion within a single institution which serves as a major regional referral centre for patients with lymphoma. In this report, we present results of the usefulness of this classification in enabling distinct, and clinically important entities to be diagnosed, in comparison with the Working Formulation [6] , and highlight areas of continuing diagnostic difficulty.
Patients and methods

Patient characteristics
Between May 1995 and December 1997 a total of 596 biopsy specimens from 557 patients with an initial diagnosis of malignant lymphoma were referred for pathology and clinical review to the CRC Wessex Medical Oncology Unit. All cases were reported according to both the Working Formulation (WF) and the R.E.A.L. Classification. For each case, difficulties relating to the classification using either the R E.A.L. or WF were documented. Following initial review, four biopsies were considered too poor to determine diagnosis (<1%). Fifty (8%) were not considered to be lymphoma. Diagnoses in these patients included carcinoma (11). reactive tissue (11). transplant-related lymphoproliferative syndrome (2). Castleman's disease (2), Langerhans" cell hisliocytosis (2) . sarcoid (I), rhabdomyosarcoma (1) . cortical thymoma (1) . and a necrotic tumour (1) . A further 77 (13%) were diagnosed as having Hodgkin's disease.
Four hundred sixty-five biopsies (78% of the total number reviewed) taken from four hundred forty-one patients were confirmed as NHL, and form the basis of this report. Of these patients, 238 were male and 203 female. The median age was 63 years (range 16-91 years). and AR). In all cases, the initial diagnosis was based on hematoxylin and eosin (H and E) -stained sections, plus, in most cases, Giemsa, periodic acid Scruff's stain and a silver impregnation method for reticulin fibre demonstration. Where available, the diagnosis was refined with the use of immunophenotypic, cytogenetic and molecular genetic data Diagnosis was problematic in 53 biopsies (11%), most commonly because the biopsy was too small, especially when needle biopsy rather than excision was performed (n = 27) This restricted the assessment of follicularity and produced poor cytological detail due to crush or shearing artifacts generated during sample collection. Occasional samples were unclassifiable because of inadequate cytological preservation (n = 3) or because material was necrotic (« = 2) or densely sclerotic (;i = 1).
Other problems included the receipt of stained sections only, without immunohistochemical preparations, and therefore had greater impact on R.E.A.L. Classification than WF. For example, it was not possible to categorize some cases of diffuse large-cell NHL as "diffuse large-B-cell NHL' in the absence of immunological data. In a small number of cases, cytological preparations only were available, for which neither classification system is satisfactory.
Categories which presented initial difficulty were biopsies with diffuse as well as follicular components within follicle centre lymphoma and those with a combination of low and intermediate grade lymphomas (e.g., extranodal marginal zone lymphomas of MALT type with accompanying diffuse large-cell NHL). By agreement, diffuse components of follicular and diffuse FCL conforming to grades 1 and 2 were not separately classified. When the appearances indicated grade 3 morphology in a diffuse component this was recorded as diffuse large-B-cell NHL in addition to appropriate classification of the follicular component. For other mixed patterns, dual classification appropriate to both the low and intermediate grade components of the neoplasm was recorded.
Only eight cases had ambiguous histology in a technically satisfactory biopsy. These were three possible mantle-cell lymphomas with atypical features, three cases of T-cell-rich diffuse large-B-cell NHL, one diffuse large-cell NHL, null forT-and B-associated antigens and one CD30+ve large-cell NHL with anaplastic cytology but a B-cell phenotype. In the latter five cases, 'best fit' categories were employed (R.E.A.L. = diffuse large-B-cell NHL; WF = ML. diffuse large cell).
Overall, following these exclusions, 412 biopsies provided adequate information for classification in R.E.A L. and WF systems, of which 354 (86%) were from newly presenting patients, and 58 (14%) from previously treated patients
Results
Histologic subtypes for the 412 classifiable biopsies according to the Working Formulation are shown in Table 1 . Fourteen percent of cases could not be readily classified into Working Formulation categories.
When the same cases were reviewed according to the R.E.A.L. Classification 367 (89%) were B cell and 38 (9%) T cell. Immunophenotype could not be determined in seven (2%) cases. All cases of B-and T-cell lymphoma were allocated to one of the 40 groupings recognised by the R.E.A.L. Classification (Table 2) . Tables 3 and 4 show the distribution of cases of B-and T-cell immuno- Abbreviations. SL -small lymphocytic; FSC -follicular: predominantly small cleaved cell; FM -follicular mixed small and large cell; FL -follicular; predominantly large cell; DSC -diffuse small cleaved cell, DM -diffuse mixed small and large cell; DLC -diffuse large cell; SNC -small non-cleaved cell; LPC -lymphoplasmacytic; LPCoid -lymphoplasmacytoid. MCL -mantle-cell lymphoma; FCL -follicle centre lymphoma (G refers to grades 1. 2 or 3; diff indicates diffuse nodal architecture); MZ E -marginal zone lymphoma. extranodal: MZ Nmarginal zone lymphoma, nodal; My -myeloma: DLBCL -diffuse large B-cell lymphoma; MLBCL -mediastinal large B-cell lymphoma;
LG uncl -low grade, unclassified, HG uncl -high grade, unclassified. Abbreviations: DM -diffuse mixed small and large cell: DLC -diffuse large cell; DLCI -diffuse large cell, immunoblastic: MF -mycosis fungoides; TPL -T-cell. prolymphocytic; MF -mycosis fungoides; PTCLU -Peripheral T-cell lymphoma. unspecified (1, 2, 3 refers to mediumsized cell, mixed medium and large cell, and large-cell categories respectively); AILD -angioimmunoblasticT-cell lymphoma; AngiocT cellangiocentric T-cell lymphoma. Int T cell -intestinal-type T-cell lymphoma. ALCL -anaplastic large-cell lymphoma: ALCL. HD likeanaplastic large-cell lymphoma.
phenotype, respectively, comparing their Working Formulation category with that to which they were assigned in the R.E.A.L. Classification. For patients with B-cell immunophenotype, 27 (7%) could not be sub-categorised in the WF, compared with only 4 (1%) in the R.E.A.L. Classification. Nine of the thirteen R.E.A.L. sub-groups showed good concordance with one or other of the main groupings of the Working Formulation. Three of the R.E.A.L. sub-groups (extranodal marginal zone lymphomas and unclassified highand low-grade lymphomas) were best classified as 'miscellaneous other' in the Working Formulation. Node-based marginal zone lymphomas could not be placed consistently in any of the WF categories.
For patients with T-cell phenotype, 26 cases (68%) could not be sub-classified in WF, compared with only one case (3%) in the R.E.A.L. Classification. There was little concurrence between the R.E.A.L. and any WF groupings which only agreed in the categorisation of mycosis fungoides. A large proportion (68%) of the T-cell lymphomas fell in the 'miscellaneous others' group of the Working Formulation. The majority of the remaining cases (18%) were placed in the diffuse large-cell category.
Discussion
Since the original description of the R.E.A.L. Classification by the I.L.S.G., its clinical utility has been investigated in several retrospective studies [2] [3] [4] [5] . The l.L.S.G. have recently reported the results of a retrospective study including 1403 patients treated at 9 major treatment centres, in which all of the histologic material was reviewed by a panel of 5 expert hematopathologists [4] . This study demonstrated the diagnostic accuracy and reproducibility of the classification and that the new entities described by the R.E.A.L. Classification represented distinct clinical conditions. The ILSG study confirmed that immunophenotyping had a significant impact upon the accuracy of diagnosis of certain NHL subtypes such as mantle cell, diffuse large-B-cell and T-cell lymphomas.
In a study from the EORTC Lymphoma Cooperative [7] . They were able to demonstrate the clinical utility of the R.E.A.L. Classification in identifying clinicopathological entities, particularly anaplastic large-cell NHL, which had a significantly different overall survival in comparison with the other T-cell subtypes studied.
A recent study from the M.D. Anderson Cancer Center has reported experience with 560 cases of aggressive NHL [3] . In this study, retrospective application of the R.E.A.L. Classification identified T-cell imunophenotype as an independent adverse prognostic factor and further identified anaplastic large cell lymphoma, angioimmunoblastic and angiocentric lymphomas as distinct clinicopathological entities.
Our study differs from those published to date in that it represents a prospective analysis of the clinical utility of the R.E.A.L. Classification, undertaken in consecutive, unselected patients with NHL seen at a single institution. The main purpose of the study was to determine whether the R.E.A.L. Classification would allow cases to be more readily categorised than the Working Formulation. We wished to determine whether this would allow clear identification of clinical entities with differing outcomes and requiring different therapeutic strategies. The preliminary results of our prospective study confirm those of the retrospective series already published.
To date, the I.L.S.G. study is the only published series to include all subtypes of NHL and therefore provides the most reliable series to compare with our own. As with the I.L.S.G. study, the two major sub-categories of NHL in our series were diffuse large-B-cell NHL and follicle centre NHL. In our study, DLBC comprised 45.9% of all cases, compared with 30.6% in the I.L.S.G. study. Follicle centre lymphoma comprised 18.7% of our cases, compared with the I.L.S.G. study (22.1%). Other subtypes in our study occurred at very similar frequencies to those reported by the I.L.S.G.
The results of our study confirm the superiority of the R.E.A.L. Classification compared with the Working Formulation in identifying clinically relevant sub-types of NHL, particularly for cases with a T-cell phenotype. These data are in agreement with most of the published studies. In the report from the I.L.S.G., addition of immunophenotypic data to routine histologic assessment allowed over 85% of T-cell NHL to be readily classified according to the R.E.A.L. Classification.
In summary, this prospective study has confirmed the clinical utility of the R.E.A.L. Classification in the setting of a single major UK cancer centre. We have been able to identify and categorize distinct clinico-pathological entities with results similar to those reported from retrospective studies. Further follow-up and larger patient numbers will be necessary to confirm these observations, and to analyse survival data with reference to clinical prognostic factors as described by the International Prognostic Index.
